Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

Hans-Jürgen Stellbrink, Chloe Orkin, Jose Ramon Arribas, Juliet Compston, Jan Gerstoft, Eric Van Wijngaerden, Adriano Lazzarin, Giuliano Rizzardini, Herman G Sprenger, John D. C. Lambert, Gunta Sture, David Leather, Sara Hughes, Patrizia Zucchi, Helen Pearce, ASSERT Study Group

    355 Citationer (Scopus)

    Abstract

    Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.
    OriginalsprogEngelsk
    TidsskriftClinical infectious diseases : an official publication of the Infectious Diseases Society of America
    Vol/bind51
    Udgave nummer8
    Sider (fra-til)963-72
    Antal sider10
    DOI
    StatusUdgivet - 15 okt. 2010

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study'. Sammen danner de et unikt fingeraftryk.

    Citationsformater